Arbutus Biopharma Corp. (NASDAQ:ABUS)’s share price shot up 4.9% during trading on Friday . The stock traded as high as $4.25 and last traded at $4.25, with a volume of 60,223 shares changing hands. The stock had previously closed at $4.05.

Several brokerages have commented on ABUS. Zacks Investment Research lowered Arbutus Biopharma Corp. from a “buy” rating to a “hold” rating in a research report on Friday, April 22nd. Wedbush restated an “outperform” rating and set a $20.00 price target on shares of Arbutus Biopharma Corp. in a report on Friday, April 22nd. Leerink Swann restated a “buy” rating and set a $12.00 price target on shares of Arbutus Biopharma Corp. in a report on Thursday, May 5th. Finally, Chardan Capital began coverage on Arbutus Biopharma Corp. in a report on Monday, May 16th. They set a “sell” rating and a $3.25 price target for the company. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $10.96.

The firm’s market capitalization is $229.97 million. The company has a 50 day moving average of $3.72 and a 200-day moving average of $3.93.

Arbutus Biopharma Corp. (NASDAQ:ABUS) last announced its quarterly earnings data on Wednesday, May 4th. The biopharmaceutical company reported ($0.19) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.20. Analysts predict that Arbutus Biopharma Corp. will post ($1.49) earnings per share for the current fiscal year.

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.